SCHEMBL29699351

SCHEMBL29699351

FC(F)(F)Oc1cccc(-c2c[nH]nn2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.52
KCNH2 Q12809 1/20 0.45
SCN10A Q9Y5Y9 1/20 0.45
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
NPY5R Q15761 1/20 0.44
PDE10A Q9Y233 2/20 0.44
ATR Q13535 1/20 0.44
USP7 Q93009 1/20 0.43
GRM5 P41594 1/20 0.43
PIM1 P11309 1/20 0.43
PIM3 Q86V86 1/20 0.43
DYRK1A Q13627 6/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
GALR1 P47211 1/20 0.40
PDE4B Q07343 1/20 0.40
DHODH Q02127 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23457617 1.00 XDH (0.52) XDHKCNH2SCN10ACTSSCTSK
SCHEMBL28320591 0.82 XDH (0.43) XDHKCNH2SCN10AGRM5PIM1
SCHEMBL12989125 0.80 SCN5A (0.47) KCNH2SCN10A
SCHEMBL1646236 0.79 GP6 (0.37) XDH
SCHEMBL7640460 0.79 XDH (0.51) XDHDYRK1A
SCHEMBL28320594 0.78 SCN9A (0.38) XDHDYRK1A
SCHEMBL5612780 0.78 IDO1 (0.54) XDHCTSS
SCHEMBL6164256 0.78 MAOB (0.42) DHODH
SCHEMBL5672965 0.77 XDH (0.51) XDHKCNH2SCN10ACTSSCTSK
SCHEMBL12096268 0.76 XDH (0.53) XDHKCNH2SCN10ACTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT XDH 1/4885KCNH2 3420/4885SCN10A 3111/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT XDH 1/4885KCNH2 4021/4885SCN10A 3398/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT XDH 1/4885KCNH2 3420/4885SCN10A 3111/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT XDH 1/4885KCNH2 3420/4885SCN10A 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.